Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06603311 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

Study acronym: BUL-STOP
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 3, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Sep 30, 2026 to Jun 30, 2026
    • Site details revised at 5 of 5 sites
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 5
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Finding biomarkers for stopping bulevirtide treatment of patients with hepatitis delta
Trial Details
NCT Number NCT06603311
Lead Sponsor Hannover Medical School
Collaborators: German Liver Foundation (DLS), HepNet Study House, German Liverfoundation
Conditions
(from sponsor)		 Compensated Liver Disease (Disorder), Hepatitis D, Chronic
Related terms Hepatitis D, Chronic
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov